HIV Vaccines

Clinical Trials Appropriate For High-Risk Cohorts In U.S.

Published in AIDS Weekly, April 23rd, 2001

by N.R. Saltmarsh, staff medical writer - A prospective study of human immunodeficiency virus type 1 (HIV-1) incidence among high-risk cohorts lends support to the idea that HIV-1 vaccine trials would be appropriate and welcomed in these populations in the United States.

"Questions exist about whether testing of preventive HIV-1 vaccines, which will require rapid recruitment and retention of cohorts with high HIV-1 seroincidence, is feasible in the United States," said G.R. Seage, III, and colleagues in the HIVNET Vaccine Preparedness Study group at the Harvard School of Public Health.

They conducted a prospective cohort study in 1995-1997 among...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-04-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry